Friday, July 31, 2026

How Trump’s Repeal of Emission Standards Could Slash Car Prices: A Guide for Asian Consumers

Trump announces the repeal of the endangerment finding, claiming it will deregulate the fossil fuel industry and reduce car prices.

Z.ai’s GLM-5.2 Surpasses Google Gemini: What This Means for AI in Asia

ZhipuAI's GLM-5.2 outperforms Google's Gemini, achieving high scores in AI evaluations and offering competitive pricing for its API.

NVIDIA’s Quantum Gambit: 576 Blackwell GPUs Power Boston Supermachine

NVIDIA is building a supercomputer with 576 GPUs to enhance quantum computing, focusing on qubit error correction and hybrid frameworks.

Tag: Celltrion

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

Celltrion Group’s 2 Trillion KRW Investment: What It Means for Global Bio Manufacturing by 2032

Celltrion Group plans a 2 trillion KRW investment to enhance production capacity and establish a leading position in global biotech.

Celltrion Expands PFS Production Capacity to 70 Million: What This Means for the Global Market

Celltrion Pharmaceutical plans to invest 2 trillion KRW to expand its pre-filled syringe production capacity to meet global demand.

How Celltrion’s Truxima Dominates the U.S. Rituximab Market: A 4-Month Winning Streak

Celltrion's Truxima leads the U.S. rituximab market for four months, gaining FDA interchangeability status, boosting growth prospects.

How Celltrion’s Omlyclo Achieved 16% Market Share in Europe: A Game-Changer for Biologics

Celltrion's biosimilars gain market share in Europe, with Omlyclo leading in Spain and Vegzelma maintaining strong presence amid competition.

Bevacizumab Breakthrough: How Celltrion’s Vegzelma Secured Coverage in Major U.S. PBMs

Celltrion's Vegzelma gains preferred status with major U.S. PBMs, enhancing prescription access and boosting market share.

Celltrion’s Truxima becomes first rituximab biosimilar in U.S. to receive interchangeability designation

Celltrion's Truxima gains FDA interchangeability status, enhancing its market position and credibility in blood cancer treatment.

Partnering Hits 180 Meetings, 2,000 Visitors…Celltrion Showcases AI and ADC Strength at BIO USA

Celltrion showcased AI-driven drug development at BIO USA, holding 180 meetings and emphasizing partnerships in antibody programs.

Celltrion Launches New Cancer Drugs in Vietnam: What You Need to Know

Celltrion launched two cancer treatments in Vietnam, expanding its portfolio and aiming for aggressive sales growth in the region.

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

Celltrion Expands AI Integration Strategy to Strengthen Global Pharmaceutical Competitiveness

Celltrion is enhancing its global competitiveness by integrating AI into drug development, manufacturing, and administration.

Celltrion’s Zymfentra Just Hit a New U.S. Prescription Record and the Growth Looks Serious

Celltrion's Zymfentra treatment saw a 185% surge in U.S. prescriptions, driven by effective marketing and reimbursement strategies.

A 90-Minute Cancer Infusion Could Soon Be Cut to 5 Minutes—and Celltrion Wants to Lead It

Celltrion has applied for EMA approval of Herzuma SC, a new breast cancer treatment, enhancing drug delivery and patient convenience.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.